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Abstract Use of biomarkers in clinical practice has proved
extremely valuable and is a rapidly expanding field. However,
despite the huge potential of biomarkers, for juvenile idio-
pathic arthritis (JIA) there are currently no validated paediatric
biomarkers available to help with setting up a more tailored
approach on which drug choice could be based, to achieve
remission early in the course of disease. Early remission
reduces burden of disease, limits side effects from toxic and
unnecessary medication, and, most importantly, enhances
quality of life. Several studies have suggested promising
biomarkers: these may be a protein, cellular component,
mRNA, or genetic component, for example a single nucleo-
tide polymorphism (SNP). Here we describe recent develop-
ments in the use of biomarkers for JIA and their potential to
assist in management of disease by predicting disease pheno-
type, severity, progression, and response to treatment, and
determining when patients have reached stable remission
and can safely discontinue treatment.
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Introduction
Juvenile idiopathic arthritis (JIA) is the most common inflam-
matory rheumatic disease in childhood, affecting one in 1000
children [1]. JIA is characterized by severe joint inflammation
in one or more joints, which persists for at least six weeks,
with disease onset before the age of 16. This heterogeneous
group of diseases can be divided into several subtypes on the
basis of clinical symptoms, medical history, and abnormalities
in laboratory measures [2].
A biomarker is a small component which is easily measur-
able in accessible patient material, e.g. blood, urine or saliva,
and is ideally obtained using a relatively non-invasive ap-
proach. Ideally, the component used as a biomarker should
be stable over time within the sample, and would be able to be
measured by an accurate, reproducible assay, at a relatively
affordable cost to health service providers. In addition, the
ideal biomarker for paediatric use would not be affected by
age-related development of children, avoiding the need for
age-specific normal-range data sets. Biomarkers are already
used in many areas of clinical practice, but most biomarker
studies focus on adults rather than children. Data from these
studies are sometimes extrapolated to children without con-
sidering differences in disease pathogenesis, age-dependent
changes in reference ranges for biological laboratory mea-
sures, growth and development of children over time, effect
of ontogeny on disease evolution and response to treatment,
and changes in phenotypic gene expression [3, 4]. Despite the
huge potential of paediatric biomarkers, for JIA there are
currently no validated paediatric biomarkers available to help
in setting up a tailored or “personalised” approach on which
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drug choice can be based. A more tailored approach would be
beneficial for patients because it could facilitate disease re-
mission at an earlier disease stage, which would reduce bur-
den of disease, limit side effects, and improve quality of life
[5].
In this review we will discuss recent developments in the
potential use of biomarkers for JIA, for predicting the type,
severity, and progression of disease after onset and the devel-
opment of complications linked to JIA, and their effect on our
ability to predict response to treatment and determine when
stable disease remission has been reached.
Use of Biomarkers to Predict Disease Phenotype,
Severity, and Progression
JIA is a heterogeneous group of disorders, and its classifica-
tion relies on both clinical findings and a small number of
biomarkers used to divide cases into relatively homogeneous
subtypes [2]. For example, the two polyarticular forms of JIA,
involving five or more joints in the first six months of disease,
are distinguished by the absence or presence of serum auto-
antibody, known as rheumatoid factor (RF), on two occasions
three months or more apart. These two clinical subgroups of
JIA are distinct in their genetics, age of onset, and prognosis
[6, 7]. Similarly, the presence of positive serum anti-nuclear
antibody (ANA) has been revealed in several studies to be
associated with an increased risk of chronic anterior uveitis in
JIA. This is a serious comorbidity of JIA, involving painless
but potentially very damaging inflammation of the anterior
chamber of the eye, which requires assiduous screening to
prevent permanent visual loss [8, 9]. A recent large cohort
study has confirmed earlier studies demonstrating that
ANA positivity is a risk factor for developing JIA-
associated uveitis [10]; current UK clinical guidelines for
how long screening should be continued include the use of
ANA positivity to direct clinical practice [11]. Thus, both
of these antibody biomarkers (RF and ANA), which are
stable proteins and are easily measured in a small volume
of serum, form part of routine clinical care and treatment
pathway decisions for JIA.
At the mild end of the JIA clinical spectrum, oligoarticular
JIA, which presents with involvement of four or fewer joints
in the first six months of disease, can lead to widely divergent
outcomes, ranging from complete remission off medication, to
a more severe, extended form of JIAwhich spreads to involve
many joints. Extended oligoarticular JIA can be highly erosive
and destructive and may be difficult to control with conven-
tional disease-modifying antirheumatic drugs (DMARDs),
frequently requiring long-term treatment with biological ther-
apy [12]. Several studies have revealed that immunological
differences between these two outcomes (persistent versus
extended oligoarticular JIA) can be observed in the inflamed
joint. For example, T cell types (e.g. regulatory T cells, or
highly proinflammatory Th17 cells) and their frequencies
differ significantly between these two clinical types [13, 14].
In addition, differences in cell frequencies, inflammatory pro-
tein levels, and gene expression can be detected in children
who will develop more severe disease, before extension oc-
curs: for example, in the so-called “extended-to-be” group of
cases, the CD4:CD8 ratio in synovial fluid is lower and the
levels of the chemokine CCL5 are higher in extended-to-be
oligoarticular JIA compared with persistent oligoarticular JIA
[15•]. In this study, analysis of differentially expressed genes
at mRNA level also provided novel insights into the patho-
logical mechanisms involved in severity, indicating the im-
portance of the complement pathway and of activated mono-
cytes in extension to more severe disease.
Studies analysing the proteome within synovial fluid have
also revealed differences between these subtypes: Gibson
et al. demonstrated that the proteome and post-translational
modifications of proteins differed between those whose dis-
ease remained mild and those who went on to develop severe
disease [16]. Validation of these findings will be required
before development of a predictive biomarker test, but this
field may well yield valuable biomarkers by which to identify
children with a poor prognosis.
Assessment of disease activity in JIA typically includes
measurement of inflammatory markers in peripheral blood,
including either the erythrocyte sedimentation rate (ESR) or
C-reactive protein (CRP) [17, 18]. Both of these inflammatory
indices have low sensitivity and specificity, because they can
be raised for many reasons other than JIA activity and in some
children do not closely mirror disease activity. Recently, the
pro-inflammatory S100 proteins, S100A8/9 (also known as
calprotectin or myeloid-related protein (MRP) 8/14) and
S100A12, have been described to be sensitive measures for
disease activity in JIA, and both correlate well with physi-
cians’ assessment of disease or with actively inflamed joints
[5, 19]. S100 proteins can be measured in serum by enzyme-
linked immune-sorbent assay (ELISA). However, the
standardisation of the measurements and the detailed proce-
dures for assay and dilution of serum samples from a wide
range of patients, with varying disease activity, are non-trivial,
complicating implementation of such a test in routine clinical
care.
The S100 proteins are released into serum at highly elevated
levels in the most severe form of JIA, systemic onset JIA
(sJIA), where they correlate well with disease activity—as
assessed by physicians’ global assessment of disease activity
(r=0.62), Childhood Health Assessment Questionnaire
(r=0.56), and active joint count (r=0.46)—and with CRP
(r=0.71) and ESR (r=0.72) (for all p<0.001) [20]. A recent
study which included measurement of serum S100 proteins has
proposed a biomarker panel for predicting flare in sJIA, com-
pared with quiescent disease [21]. The same group also tested
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the feasibility of measuring such biomarkers in urine for sJIA,
which could have many advantages for the paediatric popula-
tion, especially if testing “kits” could be designed for use in the
clinic office or even at home [22••].
One of the most severe complications of sJIA, known as
macrophage activation syndrome (MAS) or secondary
hemophagocytic lymphohistiocytosis (HLH), remains a cause
of mortality in JIA and may be difficult to distinguish from
infection [23, 24•]. A gene expression profiling study, of sJIA
patients with or without MAS compared with control patients,
identified clusters of genes that correlated with sJIA activity
and with MAS. If validated, these gene clusters could lead to
an mRNA-expression biomarker panel for predicting this
potentially life-threatening complication, or to distinguish it
from other complications. Interestingly, some of the differen-
tially expressed mRNA species identified, which differed
between children with MAS and those without, were tran-
scripts of genes known to be involved in other causes of HLH,
for example RAB27a and SH2D1A [25].
Thus, several autoantibodies are already in widespread use
as biomarkers in routine care of JIA, and some newer bio-
markers (protein, cellular, or mRNA) are under development,
for use in defining disease subtype, probable disease course,
or comorbidity.
Use of Biomarkers to Predict Response to Treatment
Recommendations for treatment of JIA are made by the
American College of Rheumatology (ACR), and are regularly
reviewed. Depending on the number of joints affected—and
after failure of monotherapy with non-steroidal anti-
inflammatory drugs (NSAIDs) and/or glucocorticoids joint
injection in cases of less severe disease—the first-line treat-
ment approach for active disease is administration of metho-
trexate (MTX). In cases of no or poor response to MTX,
biological agents, for example drugs which block tumour
necrosis factor alpha (TNFα), are added to the treatment
strategy [26]. Although many patients respond well to MTX
and reach stable disease remission, approximately 30–50 %
[27–29] of patients treated with MTX either do not respond or
respond poorly. Many studies analysing response to MTX
used the core set variables defined by Giannini et al. [17], in
which levels of response in terms of ACR30, 50, or 70 are
calculated. Those patients who fail to respond toMTX are first
exposed to MTX, and experience side effects associated with
non-response toMTX, before more effective biological agents
can be offered [5]. A biomarker (or set of biomarkers)
predicting which patients will respond to treatment would be
beneficial for the patient and prevent side effects caused by
ineffective drugs.
The pro-inflammatory S100 proteins have been shown to
correlate well with disease activity [5, 19, 20, 30], and recently
the level of S100 proteins in serum has been shown to also be
correlated with response to treatment. Six months after
starting treatment, MRP8/14 levels were lower in sJIA pa-
tients responding to MTX treatment (defined as reaching at
least ACR70), whereas MRP8/14 levels in sJIA patients not
responding to MTX treatment (ACR30) were increased or
slightly decreased. Furthermore, sJIA patients treated with
anti-IL1 or anti-TNFα had reduced MRP8/14 levels and dis-
ease activity [20]. Patients who did respond toMTX had more
active joints, higher CRP levels, and higher serum cytokine
levels before the start of MTX, which suggests that higher
disease activity is positively correlated with good response to
MTX. In addition, JIA patients with high levels of MRP8/14
before starting MTX treatment had a higher chance of good
response to MTX and had better disease outcomes (at least
ACR50) after six months of treatment than non-responders
(ACR30 or below) [5].
Differences between patients and response to treatment
could be genetic, and therefore genetic factors could be po-
tential biomarkers. Several early studies have suggested asso-
ciations between genetic polymorphisms and response to
MTX. One study identified two single nucleotide polymor-
phisms (SNPs) in the 5-aminoimidazole-4-carboxamide ribo-
nucleotide transformylase (ATIC) gene and one SNP in the
inosine triphosphate pyrophosphatase (ITPA) gene which
were found to be associated with a higher risk of poor re-
sponse to MTX treatment. Using a validation cohort, one of
the SNPs in the ATIC gene had a trend towards association
with response to MTX [31]. Genotyping of SNPs in genes
involved in the polyglutamylation process of MTX and in
cellular uptake and efflux of MTX have also shown associa-
tion with MTX response. One SNP in the adenosine-
triphosphate-binding cassette transporter B1 (ABCB1) and
one SNP in ABCC3 were found to be associated with good
response to MTX, whereas an SNP in the solute carrier 19A1
was associated with poor response to MTX [32].
In another approach, SNP genotyping of genes found to be
differentially expressed in a gene expression profiling study,
of a UK cohort of JIA patients before and after treatment with
MTX, identified three SNPs in the solute carrier family 16
member 7 (SLC16A7) gene associated with response to
MTX.Validation of these SNPs in a validation cohort revealed
significant association of one of the SNPs with non-response
to MTX [33].
A prediction model was recently developed combining
clinical and genetic variables to predict non-response of JIA
patients to MTX. In this study, response was defined as
reaching ACR70 in at least two out of three visits during the
first year of treatment. Such a model is important, because it
could help in preventing unnecessary treatment of patients
who will benefit from monotherapy with MTX and do not
need additional treatment with biologicals, which are expen-
sive and might have side effects. The clinical variable included
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in the model is the ESR. Genetic variables are SNPs in the
genes coding for methionine synthase reductase, multidrug
resistance 1 (MDR-1/ABCB1), multidrug resistance protein 1
(MRP-1/ABCC1), and proton-coupled folate transporter
(PCFT). The model had a moderate predictive power of 65 %
for the validation cohort, which might be because of the small
number of patients included in the validation cohort [34•].
Thus, evidence suggests that the pro-inflammatory S100
proteins have the potential to serve as biomarkers for
predicting response to treatment. This now needs validation
in the clinic. Furthermore, several SNPs have been found to be
associated with response to treatment, indicating that genetic
factors can also provide such biomarkers. It is probable that a
combination of genetic, biological, and clinical variables will
be required to develop accurate and robust predictive algo-
rithms with which to predict response to drug treatment of
JIA, and these may need to be disease-subtype specific.
Use of Biomarkers to Predict When Stable Remission
is Reached
Clinical remission in JIA can be reached with the use of med-
ication [35], and is ideally maintained after treatment is stopped
[1] (criteria for clinical remission on and off treatment are
described byWallace et al. [36]). However, after discontinuation
of MTX treatment, approximately 30–50 % of patients relapse
[27–29], suggesting the presence of subclinical disease activity.
This subclinical disease activity is not detectable using clinical
and standard laboratory tests, and these patients will not reach
stable remission off medication [37••]. Subclinical disease activ-
ity makes it difficult to determine when JIA patients have
reached stable remission and treatment can be stopped. There-
fore, a biomarker identifying patients at risk of disease relapse on
the basis of the inflammatory status of their disease would be
extremely valuable for improving paediatric medical care.
It has been suggested that continuation of MTX treatment
for a longer period of time after clinical remission has been
reached might reduce the risk of relapse after stopping treat-
ment. Therefore, a randomised clinical trial was conducted to
investigate whether longer treatment with MTX, for those who
achieved clinical remission, could reduce relapse after MTX
withdrawal, and which biomarkers could identify patients at
higher risk of relapse after withdrawal. Patients were continu-
ously treatedwithMTX for either six or 12months after clinical
remission was reached, and then followed after withdrawal of
MTX. However, there was no significant difference in relapse
between the two groups [37••]. On the basis of previously
published results from this group, which revealed that
MRP8/14 is a marker for subclinical disease activity [38, 39],
they determined MRP8/14 levels in serum in both groups.
Interestingly, patients with a high relapse rate after discontinu-
ation of MTX had higher levels of MRP8/14 before stopping
MTX than patients who did not flare. Thus, serum MRP8/14
levels could be a potential biomarker for predicting which
patients will achieve stable remission after withdrawal of
MTX, on the basis of inflammatory disease status [37••].
Similar results regarding the potential of MRP8/14 as a
biomarker to identify patients at risk of relapse were described
specifically for sJIA patients. Patients with new onset of active
disease or with relapse had higher levels of serum MRP8/14,
compared with patients who had reached stable remission.
Measurements of MRP8/14 levels at time of stopping treat-
ment revealed that, within up to six months, MRP8/14 levels
were higher in patients with disease relapse than patients with
no disease relapse. Prediction of patients at risk of relapse was
highly accurate, with a sensitivity of 92 % and specificity of
88 % using MRP8/14 levels >740 ng mL−1 as a cut-off [20].
Another study investigated whether S100A12 and high
sensitivity (hs) CRP could identify patients who have reached
clinical remission on treatment, and are at risk of disease
relapse after withdrawal of medication. High S100A12 and
MRP8/14 levels were observed in patients who suffered dis-
ease relapse within six months of discontinuation of treatment.
hsCRP levels did not differ between patients with disease
relapse and those in remission, but this could be caused by
the use of inclusion criteria based on normal hsCRP levels,
because patients with high hsCRP levels are more prone to
disease relapse. The patient group which relapsed within three
months of stopping treatment had higher median levels of
S100A12 and MRP8/14 compared with the group which
relapsed later. S100A12, MRP8/14, and hsCRP were sepa-
rately tested for their performance as biomarkers, and
S100A12 was the best single biomarker for predicting disease
relapse. The predictive performance could be improved by
combining S100A12 with hsCRP [40].
Treatment strategies for JIA have the objective of full
clinical remission [1], but only a very small number of patients
remain in clinical remission, off medication, for long periods
of time [41]. A recent study compared the transcriptional
profiles of patients with active disease or those in clinical
remission on medication (achieved by treatment with MTX
or MTX plus TNF blockade) with the profiles of healthy
children. Differences in transcriptional profile were observed
between patients with active disease and those in clinical
remission on medication, and also between those in remission
off treatment and healthy children. These data suggest that
being in remission does not mean a return to a “normal”
inflammatory status, but rather a “disease-controlled” state
[42]. Interestingly, the same group also demonstrated differ-
ences in transcriptional profile between patients in clinical
remission induced by treatment with MTX or with MTX plus
TNF inhibitor, and healthy individuals. This study confirmed
previous findings from the group that the inflammatory status
of patients in remission does not return to “normal”. Network
analysis suggested a function for hepatocyte nuclear factor 4
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alpha (HNF4α), which is expressed by Tcells and granulocytes,
in controlling genes associated with remission [43].
Conclusions
Use of biomarkers for childhood arthritis is a rapidly expanding
field. Such tests need to be reliable, simple to perform, econom-
ically feasible, and robust. In addition, they need to be tested and
validated for large cohorts of children with JIA. Where proved
reliable, biomarkers may assist with predicting disease type,
course or severity, with predicting response to medication and
therefore aiding treatment choices, and with accurate identifica-
tion of children who can safely stop medication once apparent
clinical remission is reached. The accurate choice of medicines
most likely to work for each child, to enable the achievement of
rapid remission for all, while avoiding unnecessary exposure to
toxic drugs for those who do not need them and reducing
unopposed inflammation to a minimum, is now the ultimate
objective of modern management of arthritis. To move rapidly
towards such ambitious objectives, multi-centre and internation-
al collaborations are needed to give every child with JIA the
opportunity to take part in biomarker and cohort studies.
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